Antibiotic Treatment for Acne Vulgaris

Seminars in Cutaneous Medicine and Surgery

Volumn 27, Issue 3, 2008, Pages 183-187

  Webster, Guy F ^a   Graber, Emmy M ^a  

^a SkinCare Physicians ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BENZAMYCIN; BENZOYL PEROXIDE; CARBAMAZEPINE; CIPROFLOXACIN; CLINDAMYCIN; CLINDAMYCIN PLUS BENZOYL PEROXIDE; CONTRACEPTIVE AGENT; COTRIMOXAZOLE; CYCLOSPORIN; DOXYCYCLINE; ERYTHROMYCIN; ISOTRETINOIN; MACROLIDE; MINOCYCLINE; ORAL CONTRACEPTIVE AGENT; RETINOID; RIFAMPICIN; TETRACYCLINE; TETRACYCLINE DERIVATIVE; THEOPHYLLINE; UNCLASSIFIED DRUG; WARFARIN;

ACNE VULGARIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ATAXIA; BONE GROWTH; BRAIN PSEUDOTUMOR; BREAST CANCER; CANCER RISK; COMBINATION CHEMOTHERAPY; CONTACT SENSITIZATION; DIARRHEA; DISEASE CONTROL; DISEASE SEVERITY; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED LUPUS LIKE DISEASE; DRUG SAFETY; ESOPHAGITIS; FEVER; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERPIGMENTATION; HYPERSENSITIVITY REACTION; LEUKOCYTOSIS; LIVER FAILURE; LIVER TOXICITY; LONG TERM CARE; LYMPHADENOPATHY; MONOTHERAPY; OBSTRUCTIVE JAUNDICE; PANCREATITIS; PATIENT COMPLIANCE; PATIENT EDUCATION; PHOTO ONYCHOLYSIS; PHOTOSENSITIVITY; PHOTOTOXICITY; PHYSICIAN; PSEUDOMEMBRANOUS COLITIS; PSEUDOPORPHYRIA; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; THROMBOCYTOPENIC PURPURA; TOOTH DISCOLORATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UREMIA; URTICARIA; VASCULITIS; VERTIGO;

ACNE VULGARIS; ANTI-INFECTIVE AGENTS; BENZOYL PEROXIDE; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; MACROLIDES; TETRACYCLINE; TETRACYCLINE RESISTANCE;

EID: 50949133988     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sder.2008.07.001     Document Type: Review

References (54)

1. Webster C.F. Acne vulgaris. Br Med J 325 (2002) 475-479
2. Kirschbaum J., and Kligman A. The pathogenic role of Corynebacterium acnes in acne vulgaris. Arch Dermatol 88 (1963) 832-833
3. Brüggemann H., Henne A., Hoster F., et al. The complete genome sequence of Propionibacterium acnes, a commensal of human skin. Science 305 (2004) 671-673
4. Skidmore R., Kovach R., Walker C., et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 139 (2003) 459-464
5. Zouboulis C.C., and Piquero-Martin J. Update and future of systemic acne treatment. Dermatology 206 (2003) 37-53
6. Parsad D., Pandhi R., and Nagpal R. Azithromycin monthly pulse vs daily doxycyline in the treatment of acne vulgaris. J Dermatol 28 (2001) 1-4
7. Leyden J.J., McGinley K.J., Cavelieri S., et al. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 8 (1984) 41-45
8. Ross J.I., Snelling A.M., Eady E.A., et al. Phenotypic and genotypic characterization of antibiotic resistant Propionibacterium acnes isolated from acne patients attending dermatology clinicsin Europe, the USA, Japan and Australia. Br J Derm 144 (2001) 339-346
9. Mills O., Thornsberry C., Cardin C.W., et al. Bacterial resistance and outcome following three months of topical acne therapy with 2% erythromycin gel vs its vehicle. Acta Dermatol Venerol 82 (2002) 260-265
10. Vowels B.R., Feingold D.S., Sloughfy C., et al. Effects of topical erythromycin on the ecology of aerobic cutaneous bacterial flora. Antimicrob Agents Chemother 40 (1996) 2598-2604
11. Leyden J., Kaidbey K., and Levy S.F. The combination formulation of clindamycin 1% plus benzoyl peroxide 5% vs. three different formulations of topical clindamycin alone in the reduction of Propionibacterium acnes. Am J Clin Dermatol 4 (2001) 263-266
12. Goodheart G.L. Further evidence for the role of bivalent cations in human polymorphonuclear leukocyte locomotion. J Reticuloendothelial Soc 25 (1979) 545-554
13. Webster G.F., Toso S.M., and Hegeman L. Inhibition of a model of granuloma formation by tetracyclines and ciprofloxacin: Involvement of protein kinase C. Arch Dermatol 130 (1994) 748-752
14. D'Agostino P., La Rosa M., Barbera C., et al. Doxycycline reduces mortality to lethal endotoxemia by reducing nitric oxide synthesis via an interleukin-10-independent mechanism (Erratum in: J Infect Dis 177:1778, 1998). J Infect Dis 177 (1998) 489-492
15. Golub L.M., Lee H.M., Lehrer G., et al. Minocycline reduces gingival collagenolytic activity during diabetes. J Perio Res 18 (1983) 516-526
16. Maata M., Kari O., Tervahartiala T., et al. Tear fluid levels of MMP-8 are elevated in ocular rosacea: Treatment effect of oral doxycycline. Graefs Arch Clin Exp Ophth 244 (2006) 957-962
17. Sobrin L., Liu Z., Monroy D.C., et al. Regulation of MMP-9 activity in human tear fluid and corneal epithelial culture supernatant. Invest Ophth Vis Sci 41 (2000) 1703-1709
18. Sapadin A.N., and Fleishmajer R. Tetracyclines: Non-antibiotic properties and their clinical implications. J Am Acad Dermatol 54 (2006) 258-265
19. Dezube B.J., Krown S.E., Lee J.Y., et al. Ramdomized phase 2 trial of MMP inhibitor col-3 in AIDS-related Kaposi's sarcoma. J Clin Oncol 24 (2006) 1389-1394
20. Onoda T., Ono T., Dhar D.K., et al. Tetracyclines analogues doxycycline and col 3 induce caspase dependent and independent apoptosis in human colon cancer cells. Int J Cancer 118 (2006) 1309-1315
21. Acharya M.R., Venitz J., Figg W.D., et al. Chemically modified tetracyclines as inhibitors f matrix metalloproteinases. Drug Resit Updat 7 (2004) 195-208
22. Webster G.F., McGinlery K.J., and Leyden J.J. Inhibition of lipase production in Propionibacterium acnes by sub minimal inhibitory concentrations of tetracycline and erythromycin. Br J Dermatol 105 (1981) 453-457
23. Webster G.F., Leyden J.J., McGinley K.J., et al. Suppression of polymorphonuclear leukoicytechemotactic factor production by sub minimal inhibitory concentrations of tetracycline, minocycline, ampicillin and erythromycin. Antimicrob Agents Chemother 21 (1982) 770-772
24. Sanchez J., Somolinos A.L., Almodovar P.I., et al. A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. J Am Acad Dermatol 53 (2005) 791-797
25. Emingil G., Atilla G., Sorsa T., et al. The effect of adjunctive low-dose doxycycline therapy on clinical parameters and gingival crevicular fluid matrix metalloproteinase-8 levels in chronic periodontitis. J Periodontol 75 (2004) 106-115
26. Theobald K., Bradshaw M., and Leyden J. Anti-inflammatory dose doxycycline (40 mg controlled-release) confers maximum anti-inflammatory efficacy in rosacea. Skin Med 6 (2007) 221-226
27. Zaenglein A.L., Graber E.M., Thiboutot D.M., et al. Acne vulgaris and acneiform eruptions. In: Wolff K., Katz S.I., and Goldsmith L.A. (Eds). Fitzpatrick's Dermatology in General Medicine. (ed 7) (2007), McGraw-Hill Professional Publishing, New York 690-702
28. Layton A.M., and Cunliffe W.J. Phototoxic eruptions due to doxycycline-a dose related phenomenon. Clin Exp Dermatol 18 (1993) 425-427
29. Elkayam O., Yaron M., and Caspi D. Minocycline induced autoimmune syndromes: An overview. Semin Arthritis Rheum 28 (1999) 392-297
30. Phillips M.E., Eastwood J.B., Curtis J.R., et al. Tetracycline poisoning in renal failure. Br Med Jr 2 (1974) 149-151
31. Cooper A. Systematic review of Propionibacterium acnes resistance to systemic antibiotics. Med J Aus 169 (1998) 259-261
32. Leyden J.J. Current issues in antimicrobial therapy for the treatment of acne. J Eur Acad Dermatol Venereol 3 suppl 15 (2001) 51-55
33. Hubbell C.G., Hobbs E.R., Rist T., et al. Efficacy of minocycline compared with tetracycline in treatment of acne vulgaris. Arch Dermatol 118 (1982) 989-992
34. Leyden J.J. The antimicrobial effects in vivo of minocycline, doxycycline and tetracycline in humans. J Derm Treat 7 (1996) 223-225
35. Bottomly W.W., and Cunliffe W.J. Oral trimethoprim as a third line antibiotic in the management of acne vulgaris. Dermatology 187 (1993) 193-196
36. Sykes N.L., and Webster G.F. Acne: A review of optimum treatment Drugs 48 (1994) 59-70
37. Fernandez E.M., Zaenglein A.L., and Thiboutot D.M. Acne treatment methodologies. In: Draelos Z.D., and Thaman L.A. (Eds). Cosmetic Formulation of Skin Care Products (2006), Taylor and Francis Group, London 273-296
38. Webster G.F. Acne vulgaris. Brit Med J 325 (2002) 475-479
39. Bandmann H.J., and Agathos M. Post-therapeutic benzoyl peroxide contact allergy in ulcus cruris patients. Hautzert 36 (1985) 670-674
40. Cotterill J.A. Benzoyl peroxide. Acta Dermatol Venerol 60 (1980) 57-63
41. Mills O.H., Kligman A.M., Pochi P., et al. Comparing 2.5%, 5% and 10% benzoyl peroxide in inflammatory acne vulgaris. Int J Dermatol 25 (1986) 664-667
42. Leyden J., Kaidbey K., and Levy S.F. The combination formulation of clindamycin 1% plus benzoyl peroxide 5% vs. three different formulations of topical clindamycin alone in the reduction of Propionibacterium acnes. Am J Clin Dermatol 4 (2001) 263-266
43. Ellis C.N., Leyden J., Katz H.I., et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis 67 (2001) 257-259
44. Eady E.A., Bojar R.A., Jones C.E., et al. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria. Br J Dermatol 134 (1996) 107-113
45. Velicer C.M., Heckbert S.R., Rutter C., et al. Association between antibiotic use prior to breast cancer diagnosis and breast tumor characteristics. Cancer Causes Control 17 (2006) 307-313
46. Velicer C.M., Heckbert S.R., Lampe J.W., et al. Antibiotic use in relation to the risk of breast cancer. JAMA 291 (2004) 827-835
47. Margolis D.J., Bowe W.P., Hoffstad O., et al. Antibiotic treatment of acne may be associated with upper respiratory tract infections. Arch Dermatol 141 (2005) 1132-1136
48. Leyden J.J., McGinley K.J., Cavalieri S., et al. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 8 (1983) 41-45
49. Eady E.A., Cove J.H., Holland K.T., et al. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 121 (1989) 51-57
50. Coates P., Vyakrnam S., Ravenscroft J.C., et al. Efficacy of oral isotretinoin in the control of skin and nasal colonization by antibiotic-resistant propionibacteria in patients with acne. Br J Dermatol 153 (2005) 1126-1136
51. Cunliffe W.J., Holland K.T., Bojar R., et al. A: randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther 24 (2002) 1117-1133
52. Archer J.S., and Archer D.F. Oral contraceptive efficacy and antibiotic interaction: A myth debunked. J Am Acad Dermatol 46 (2002) 917-923
53. Friedman G.D., Oestreicher N., Chan J., et al. Antibiotics and risk of breast cancer: Up to 9 years of follow-up of 2.1 million women. Cancer Epidemiol Biomarkers Prev 15 (2006) 2102-2106
54. Tamim H.M., Hanley J.A., Hajeer A.H., et al. Risk of breast cancer in relation to antibiotic use. Pharmacoepidemiol Drug Saf 17 (2008) 144-150